MOLOGEN AG: Good tolerance of the colorectal cancer medication MGN1703 in phase II/III study – data will be presented at the symposium of ASCO in San Francisco.

 

Leading oncologists from throughout the world will come together on these days for the Gastrointestinal Cancers Symposium in San Francisco, in order to share information about the latest scientific breakthroughs. Particular attention should also be given to the development of the colorectal cancer medication MGN1703 from MOLOGEN AG, which is currently in a phase II/III clinical study.

 

Berlin, 01/21/2011 - MOLOGEN AG will be reporting at the 2011 Gastrointestinal Cancers Symposium in San Francisco on their clinical study of the intestinal cancer medication MGN1703. This symposium of the American Society of Clinical Oncology (ASCO) is the central panel for gastro-intestinal cancer illnesses, where oncologists from the entire world will come to be informed about the research results of their colleagues.

According to the statements of the researchers from MOLOGEN AG, the clinical study for MGN1703, for which the interim evaluation is expected in mid-year, has shown very good tolerance up until now. This is worth noting, because for this current study phase the highest dosage from the previous phase 1b was selected and continued. The applied dosage is approx. 5-10x higher than the dosage which has been used up to now by competitors in clinical studies. The dSLIM® DNAmolecule that was developed and patented by MOLOGEN is extremely low on side effects thanks to its unique structure, making this dosage possible.

Dr. Matthias Schroff, scientist and chairman of the board of MOLOGEN AG comments: "We are pleased that our colorectal cancer medication is being well tolerated during the current study. This encourages us in our efforts to offer future patients a cancer medication without significant side effects.“

 

The cancer medication MGN1703 is currently being investigated in the course of a phase II/III clinical study that is relevant for the approval in the treatment of metastasized colorectal cancer. The goal of the study is to significantly prevent the progression of the cancer significantly longer than has been possible with the treatment methods up to now. The study is currently being conducted at various study centers in Germany, France and Austria. The first results will tentatively be available after an interim evaluation in mid 2011.

 

Patient information

www.mologen.com/data/Deutsch/09_01_Patienteninfo

 

Product information and study centers

www.mologen.com/data/Deutsch/09_02_MGN1703

 

Study portal

The study is recorded on all relevant Internet portals. To overview see website:

www.mologen.unternehmenskommunikation.com/D/studienportale

 

Hotline

A study hotline at MOLOGEN AG for MGN1703 provides information individually and in strict confidence in accordance with medical discretion to interested doctors and patients on: +49 (0)800 646 1703

 www.mologen.com

 

About MOLOGEN AG

MOLOGEN AG, a German bio-pharmaceutical company based in Berlin, specializes in the research and development of innovative medicaments based on DNA structures. Activities focus on numerous product developments relevant to the immune system, on the one hand vaccines against serious infections and on the other hand cancer medicaments. MOLOGEN AG is one of the few biotechnology companies worldwide with a well-compatible DNA-based cancer treatment in the clinical development stage.

 

Stock in MOLOGEN AG is listed in the Prime Standard of the German stock exchange

(ISIN DE 0006637200).

 

Association memberships:

BIO Deutschland e.V.  |  DECHEMA - Gesellschaft für Chemische Technik und Biotechnologie e.V.  |  Deutsche Industrievereinigung Biotechnologie (DIB)  |  Stifterverband für die Deutsche Wissenschaft e.V.  |  Vereinigung deutscher Biotechnologie-Unternehmen (VBU)  |  Verband Forschender Arzneimittelhersteller e.V. (VFA)  |  Verband der Chemischen Industrie e.V. (VCI)

 

MIDGE®, dSLIM® and MOLOGEN® are registered trademarks of MOLOGEN AG.

 

MOLOGEN AG

 

PRESS SERVICE

Prof. Peter W. Hübner

Head of Corporate Communications

Tel:  +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50

[email protected]

 

INVESTOR RELATIONS:

Jörg Petraß

Tel:  +49 - 30 - 84 17 88 - 13
Fax: +49 - 30 - 84 17 88 - 50

[email protected]

 

External Investor Relations

Kirchhoff Consult AG

Janina Wismar M.A.

Tel:  +49 - 40 - 60 91 86 - 50

Fax: +49 - 40 - 60 91 86 - 16

[email protected]

 

Risk notice regarding forward-looking statements

Certain statements in this report contain forward-looking expressions or corresponding expressions with negation or deviating versions thereof or comparable terminology, these are designated as forward-looking statements. In addition, all information given here that relates to planned or future results from business sectors, financial figures, developments of the financial situation or other financial figures or statistical statements, contain such forward-looking statements. The company advises potential investors to not rely on these forward-looking statements as a prediction of actual future events. The company is not obliged to update these forward-looking statements that only reflect the situation on the day of publication, and rejects any liability therefor.